ProCE Banner Activity

KEYNOTE-756: Phase III Trial of Neoadjuvant Pembrolizumab vs Placebo Plus CT Followed by Adjuvant Pembrolizumab vs Placebo Plus ET in High-Risk, ER+/HER2- EBC

Conference Coverage

The addition of pembrolizumab to neoadjuvant chemotherapy improved pathologic complete response rate vs placebo plus chemotherapy in patients with high-risk, ER+/HER2- early breast cancer.

Released: December 07, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., Gilead Sciences, Inc., Lilly, Merck Sharp & Dohme LLC, and Seagen Inc.


Daiichi Sankyo, Inc.

Gilead Sciences, Inc.


Merck Sharp & Dohme, LLC

Seagen Inc.